Peptide API Manufacturing in AI Search: The Biggest AI Visibility Problems and How We'd Fix Them
This analysis is based on the source benchmark: Peptide API Manufacturing AI visibility benchmark
On this report
Key Takeaways
- Bachem leads the peer set by a wide margin in mentions, recommendations, and first-place placements.
- AmbioPharm and Biosynth Peptide Division form a second tier with solid recommendation rates but fewer first-place rankings.
- Several companies have conflicting claims in AI answers, including ownership, eligibility, revenue, and inspection timing.
- The recommended next steps are baseline tracking, fact-checking disputed claims, and reviewing owned and third-party pages against buyer questions.
Companies covered: CSBio, Bachem, AmbioPharm, CPC Scientific, PolyPeptide Group, CordenPharma Peptides, Biosynth Peptide Division
Answer Capsule
The November 2026 Peptide API Manufacturing benchmark compares 7 companies across 303 AI answers that met its inclusion rules. Bachem recorded 258 mentions and 173 recommendations (57.10% of the answers). Being mentioned means appearing in an answer; being recommended means receiving an affirmative endorsement.
We examine each company, establish the current research baseline, and set out a five-step plan for improving the information AI systems can draw on. The work starts with measuring visibility and checking conflicting claims, then moves to company pages, relevant publishers and buyer questions. The cited pages need review before any correction request, and the research does not establish what caused recommendation differences or promise future gains.
Executive industry diagnosis
Questions This Section Answers
- What does the Peptide API Manufacturing benchmark show about mentions, recommendations and placement?
Rank | Company | Mentions | Mention rate | Recommendations | Recommendation rate | Top 3 | Top 3 rate | #1 | #1 rate |
|---|---|---|---|---|---|---|---|---|---|
1 | Bachem | 258 | 85.15% | 173 | 57.10% | 152 | 50.17% | 113 | 37.29% |
2 | AmbioPharm | 110 | 36.30% | 82 | 27.06% | 63 | 20.79% | 8 | 2.64% |
3 | Biosynth Peptide Division | 71 | 23.43% | 63 | 20.79% | 42 | 13.86% | 6 | 1.98% |
4 | PolyPeptide Group | 70 | 23.10% | 46 | 15.18% | 34 | 11.22% | 1 | 0.33% |
5 | CPC Scientific | 53 | 17.49% | 32 | 10.56% | 18 | 5.94% | 3 | 0.99% |
6 | CordenPharma Peptides | 49 | 16.17% | 21 | 6.93% | 16 | 5.28% | 1 | 0.33% |
7 | CSBio | 8 | 2.64% | 6 | 1.98% | 0 | 0.00% | 0 | 0.00% |
Bachem dominates this peer set on every recorded measure, appearing in most answers and carrying an endorsement in a clear majority of them. Its first-place count is unusually large relative to the rest of the field, which suggests answers often name it as the leading option rather than one of several.
AmbioPharm and Biosynth Peptide Division form a second tier: both are mentioned in roughly a third or a quarter of answers and are recommended often, but their first-place appearances are far fewer. That gap between being recommended and being named first is the practical distinction worth studying.
PolyPeptide Group, CPC Scientific and CordenPharma Peptides appear less often and are endorsed less often still, with first-place placements rare. CSBio sits at the edge of the set, with a handful of mentions and endorsements but no leading placement.
The pattern suggests answers concentrate leadership on one manufacturer while treating others as credible alternatives. For the agency, the useful work is to understand which questions produce that concentration and to verify the claims behind it before proposing any changes.
What changed since last month
Questions This Section Answers
- What changed across the usable monthly Peptide API Manufacturing snapshots?
Company | Nov 2026 |
|---|---|
Bachem | 173 / 303 (57.10%) |
AmbioPharm | 82 / 303 (27.06%) |
Biosynth Peptide Division | 63 / 303 (20.79%) |
PolyPeptide Group | 46 / 303 (15.18%) |
CPC Scientific | 32 / 303 (10.56%) |
CordenPharma Peptides | 21 / 303 (6.93%) |
CSBio | 6 / 303 (1.98%) |
Only months with verified results are shown. Monthly sample coverage is listed in Methodology.
This edition is the first broad baseline, so the monthly figures should be read as a single snapshot rather than a movement from earlier months. Earlier editions asked a narrower set of questions, which means their numbers are not comparable with these.
What the table shows is the current spread of endorsements across the peer set, with Bachem well ahead and the remaining companies clustered below. No conclusion about improvement or decline can be drawn from one month.
Future editions that use the same screening scope can be compared with this baseline. Until then, the agency should document how questions are selected and answers screened so later comparisons are like-for-like.
AI recommendation trend
Observed recommendation rate (%), Nov 2026
- Bachemno changeNov 202657.10%
- AmbioPharmno changeNov 202627.06%
- Biosynth Peptide Divisionno changeNov 202620.79%
- PolyPeptide Groupno changeNov 202615.18%
- CPC Scientificno changeNov 202610.56%
- CordenPharma Peptidesno changeNov 20266.93%
- CSBiono changeNov 20261.98%
Separate selected monthly samples. Missing points are unavailable, not zero. Provider/prompt equivalence is unverified; rate movement does not demonstrate causation.
Company-by-company findings
CSBio
Questions This Section Answers
- What measured visibility pattern and review priority does CSBio have in Peptide API Manufacturing?
CSBio recorded 8 mentions (2.64%) and 6 recommendations (1.98%) across 303 answers included in the benchmark. Top 3 placements numbered 0; first-place recommendations numbered 0. Framing among its mentions was 6 positive, 2 neutral and 0 negative.
This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.
AI answers contained 0 conflicting claims about CSBio: 0 critical, 0 high, 0 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.
No results are available for this part of the analysis.
Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.
Question observed in the research | Benchmark answers to this question | Company mentions | Company recommendations |
|---|---|---|---|
What are the best peptide companies in the US? | 4 | 1 | 1 |
What companies sell the most peptides? | 5 | 1 | 1 |
These are recorded answer observations, not search volume, verified demand, or proof of missing website content.
Selected owned-page review candidate: https://csbio.com/blog/choosing-a-peptide-synthesizer.
Selected third-party review candidate: https://bachem.com/.
CSBio's few appearances mostly carried positive wording and an endorsement, yet none placed it first. That pattern suggests answers treat it as a credible option rather than a leading one, though the small number of observations limits how much weight to place on it.
A sensible next step is a conditional page review of the supplied owned-page candidate, checking whether it answers the buyer questions where CSBio appeared. Any edit would follow current primary-source verification, not the answer text alone.
Bachem
Questions This Section Answers
- What measured visibility pattern and review priority does Bachem have in Peptide API Manufacturing?
Bachem recorded 258 mentions (85.15%) and 173 recommendations (57.10%) across 303 answers included in the benchmark. Top 3 placements numbered 152; first-place recommendations numbered 113. Framing among its mentions was 194 positive, 64 neutral and 0 negative.
This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.
AI answers contained 13 conflicting claims about Bachem: 0 critical, 9 high, 1 medium, 3 low. Of these, 9 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.
Review topic | Severity | Recorded AI claim A | Recorded AI claim B |
|---|---|---|---|
peptide revenue / scale | medium | CHF 605M peptide API revenue | CHF 695.1 million in 2025 group sales |
who can buy (eligibility) | high | B2B/institutional only; not individual consumers | anyone can buy online directly |
Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.
Question observed in the research | Benchmark answers to this question | Company mentions | Company recommendations |
|---|---|---|---|
What are the biggest peptide companies? | 5 | 5 | 4 |
What companies sell the most peptides? | 5 | 5 | 4 |
These are recorded answer observations, not search volume, verified demand, or proof of missing website content.
Selected owned-page review candidate: https://bachem.com/.
Selected third-party review candidate: https://alibaba.com/supplier/bachem-peptides.html.
Bachem's reach and placement are the strongest in the set, and its mentions carried no negative framing. The recorded conflicts are the more actionable finding: answers disagree on who may buy from Bachem and on its revenue scale, and the eligibility conflict is rated high priority.
Proposed work is a scoped fact check against current primary sources, followed by a page brief for the supplied owned-page candidate if a gap is confirmed. The third-party candidate would be reviewed separately, with no correction requested until its current contents are verified.
AmbioPharm
Questions This Section Answers
- What measured visibility pattern and review priority does AmbioPharm have in Peptide API Manufacturing?
AmbioPharm recorded 110 mentions (36.30%) and 82 recommendations (27.06%) across 303 answers included in the benchmark. Top 3 placements numbered 63; first-place recommendations numbered 8. Framing among its mentions was 83 positive, 27 neutral and 0 negative.
This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.
AI answers contained 3 conflicting claims about AmbioPharm: 0 critical, 0 high, 3 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.
Review topic | Severity | Recorded AI claim A | Recorded AI claim B |
|---|---|---|---|
ownership (part of CordenPharma) | medium | AmbioPharm is an independent manufacturer (no CordenPharma ownership) | AmbioPharm is now part of CordenPharma |
ownership / acquisition status | medium | acquired by CordenPharma (August 2026) | independent specialized manufacturer (no acquisition mentioned) |
Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.
Question observed in the research | Benchmark answers to this question | Company mentions | Company recommendations |
|---|---|---|---|
What are the biggest peptide companies? | 5 | 4 | 3 |
What companies sell the most peptides? | 5 | 3 | 3 |
These are recorded answer observations, not search volume, verified demand, or proof of missing website content.
Selected owned-page review candidate: https://ambiopharm.com/.
Selected third-party review candidate: https://bachem.com/.
AmbioPharm is recommended in most of the answers that mention it, but it rarely takes first place. Reach and endorsement are therefore stronger than leading position, and the two should be tracked separately rather than treated as one measure.
The recorded conflicts concern ownership, including whether AmbioPharm is part of CordenPharma. Proposed work is a fact check of the ownership record against current primary sources, then a page brief for the supplied owned-page candidate if the review supports one.
CPC Scientific
Questions This Section Answers
- What measured visibility pattern and review priority does CPC Scientific have in Peptide API Manufacturing?
CPC Scientific recorded 53 mentions (17.49%) and 32 recommendations (10.56%) across 303 answers included in the benchmark. Top 3 placements numbered 18; first-place recommendations numbered 3. Framing among its mentions was 34 positive, 19 neutral and 0 negative.
This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.
AI answers contained 1 conflicting claim about CPC Scientific: 0 critical, 0 high, 0 medium, 1 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.
Review topic | Severity | Recorded AI claim A | Recorded AI claim B |
|---|---|---|---|
FDA pre-license inspection date for Hangzhou facility | low | FDA pre-license inspection completed August 2026 | FDA inspections already completed (no future date) |
Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.
Question observed in the research | Benchmark answers to this question | Company mentions | Company recommendations |
|---|---|---|---|
What are the biggest peptide companies? | 5 | 4 | 3 |
What companies sell the most peptides? | 5 | 3 | 2 |
These are recorded answer observations, not search volume, verified demand, or proof of missing website content.
Selected owned-page review candidate: https://cpcscientific.com/.
Selected third-party review candidate: https://en.wikipedia.org/wiki/CPC_Scientific.
CPC Scientific appears in a modest share of answers and is endorsed in most of those, with a few leading placements. Its single recorded conflict concerns an inspection date and is rated low priority, so it is a candidate for verification rather than urgent correction.
Proposed work is a light fact check of the inspection record and a review of the supplied owned-page candidate against the questions where CPC Scientific appeared. Any change would wait on current primary-source confirmation.
PolyPeptide Group
Questions This Section Answers
- What measured visibility pattern and review priority does PolyPeptide Group have in Peptide API Manufacturing?
PolyPeptide Group recorded 70 mentions (23.10%) and 46 recommendations (15.18%) across 303 answers included in the benchmark. Top 3 placements numbered 34; first-place recommendations numbered 1. Framing among its mentions was 48 positive, 22 neutral and 0 negative.
This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.
AI answers contained 0 conflicting claims about PolyPeptide Group: 0 critical, 0 high, 0 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.
No results are available for this part of the analysis.
Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.
Question observed in the research | Benchmark answers to this question | Company mentions | Company recommendations |
|---|---|---|---|
What companies sell the most peptides? | 5 | 5 | 4 |
What are the biggest peptide companies? | 5 | 4 | 3 |
These are recorded answer observations, not search volume, verified demand, or proof of missing website content.
Selected owned-page review candidate: https://polypeptide.com/.
Selected third-party review candidate: https://indeed.com/cmp/Polypeptide-Laboratories/reviews.
PolyPeptide Group is mentioned in roughly a quarter of answers and endorsed in many of them, but it almost never takes first place. That makes it a strong alternative in answers rather than a leading recommendation.
No conflicting claims were recorded for it, so the priority is a page review of the supplied owned-page candidate, checking whether it addresses the buyer questions where the company appeared. Edits would follow verification, not the answer text.
CordenPharma Peptides
Questions This Section Answers
- What measured visibility pattern and review priority does CordenPharma Peptides have in Peptide API Manufacturing?
CordenPharma Peptides recorded 49 mentions (16.17%) and 21 recommendations (6.93%) across 303 answers included in the benchmark. Top 3 placements numbered 16; first-place recommendations numbered 1. Framing among its mentions was 23 positive, 26 neutral and 0 negative.
This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.
AI answers contained 0 conflicting claims about CordenPharma Peptides: 0 critical, 0 high, 0 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.
No results are available for this part of the analysis.
Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.
Question observed in the research | Benchmark answers to this question | Company mentions | Company recommendations |
|---|---|---|---|
What companies sell the most peptides? | 5 | 4 | 4 |
What are the biggest peptide companies? | 5 | 4 | 3 |
These are recorded answer observations, not search volume, verified demand, or proof of missing website content.
Selected owned-page review candidate: https://cordenpharma.com/how-we-deliver/technology-platforms/peptides-platform/.
Selected third-party review candidate: https://biosynth.com/peptides.
CordenPharma Peptides is mentioned less often than the leaders and endorsed in fewer than half of those mentions, with neutral framing common. It rarely takes first place, so its presence is broader than its endorsement strength.
No conflicting claims were recorded. Proposed work is a page review of the supplied owned-page candidate and a check of whether the peptide platform page answers the buyer questions where the company appeared, with any edit conditional on verification.
Biosynth Peptide Division
Questions This Section Answers
- What measured visibility pattern and review priority does Biosynth Peptide Division have in Peptide API Manufacturing?
Biosynth Peptide Division recorded 71 mentions (23.43%) and 63 recommendations (20.79%) across 303 answers included in the benchmark. Top 3 placements numbered 42; first-place recommendations numbered 6. Framing among its mentions was 63 positive, 8 neutral and 0 negative.
This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.
AI answers contained 0 conflicting claims about Biosynth Peptide Division: 0 critical, 0 high, 0 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.
No results are available for this part of the analysis.
Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.
Question observed in the research | Benchmark answers to this question | Company mentions | Company recommendations |
|---|---|---|---|
What is the most reliable peptide company? | 3 | 2 | 2 |
What is the most trusted peptide company? | 4 | 2 | 2 |
These are recorded answer observations, not search volume, verified demand, or proof of missing website content.
Selected owned-page review candidate: https://biosynth.com/peptides.
Selected third-party review candidate: https://phoenixpeptide.com/product_category/peptides/.
Biosynth Peptide Division is mentioned in about a quarter of answers and endorsed in most of them, a higher endorsement share than several larger peers. Its leading placements are few, so it reads as a trusted alternative rather than the default first choice.
No conflicting claims were recorded. The observed questions about reliability and trust make a useful starting point for a page brief on the supplied owned-page candidate, subject to verification of current contents.
/ Take the next step
Want to Understand Your AI Citation Footprint?
We start every engagement with a full audit of how AI systems reference your brand today.
Measurable, Repeatable Programme
Build a durable foundation of credible citations that compounds over time and continues to influence AI answers as new queries emerge
Citation Architecture Review
Identify which high-authority community sources are and aren't working in your favour across AI platforms.
AI Visibility Audit
Understand exactly how LLMs are referencing your brand today and which sources are shaping those answers.
The CiteWorks five-step improvement plan
Step 1. Establish the baseline
Questions This Section Answers
- What should the agency deliver when it works to establish the baseline for Peptide API Manufacturing?
Build a scorecard that records, for each company, the questions asked, the answers captured and the placement observed, so later editions can be compared on the same basis. The scorecard should note the screening rules and the services covered.
Documenting comparability now prevents later months from being read as trends when the question set has changed. Each record needs an owner and a review status.
Step 2. Verify disputed facts
Questions This Section Answers
- What should the agency deliver when it works to verify disputed facts for Peptide API Manufacturing?
AI answers contained 17 conflicting claims across 3 companies. Another 0 possible conflicts were excluded because their company matches were uncertain. The conflicting claims need fact-checking before any corrections are proposed.
Seventeen conflicting claims were recorded across three companies, and a further group was set aside because the company match was uncertain. Those excluded items stay outside the correction queue until the entity is resolved.
Fact-checking comes first: confirm the entity, date and source behind each disputed claim. Only then should the agency decide whether a correction is warranted, and any proposed change needs current primary-source support.
Step 3. Review owned pages
Questions This Section Answers
- What should the agency deliver when it works to review owned pages for Peptide API Manufacturing?
Assign page briefs to the supplied owned-page candidates, one per company, framed around the questions where that company appeared. Each brief should list the buyer questions to answer and the facts that need confirmation before drafting.
Briefs are proposals for review, not instructions to edit. No page should be changed until its current contents and the underlying facts have been checked against primary sources.
Step 4. Review third-party sources
Questions This Section Answers
- What should the agency deliver when it works to review third-party sources for Peptide API Manufacturing?
Prepare source-review packages for the supplied third-party candidates, starting with the pages that appear most often across captured answers. Each package should record what the page currently says and which company claims it touches.
A citation does not show that a page influenced an answer, so requests should be framed as verification rather than correction. Nothing is requested until the page contents are confirmed.
Step 5. Address buyer questions and measure again
Questions This Section Answers
- What should the agency deliver when it works to address buyer questions and measure again for Peptide API Manufacturing?
Turn the observed buyer questions into content briefs that answer them directly, using verified company facts. These briefs can guide owned pages and publisher conversations without asserting what any page currently lacks.
Measurement should follow later, using the same screening scope as this baseline. Delivered work is tracked separately from answer outcomes, and no gain is assumed from publishing alone.
Third-party authority and citation opportunities
Questions This Section Answers
- Which cited publisher pages support targeted source review in Peptide API Manufacturing?
Publisher page selected for review | Citation appearances in all captured answers | Companies covered by the page selection |
|---|---|---|
https://bachem.com/ | 99 | CSBio, AmbioPharm |
https://biosynth.com/peptides | 70 | CSBio, CordenPharma Peptides |
https://phoenixpeptide.com/product_category/peptides/ | 51 | CordenPharma Peptides, Biosynth Peptide Division |
https://onetwenty.com/blog/peptide-companies | 57 | Biosynth Peptide Division |
https://rootsanalysis.com/key-insights/top-10-peptide-synthesis-companies.html | 12 | AmbioPharm |
https://en.wikipedia.org/wiki/CPC_Scientific | 7 | CPC Scientific |
https://indeed.com/cmp/Polypeptide-Laboratories/reviews | 3 | PolyPeptide Group |
https://cetaf.org/polypeptide-functional-group-zone/ | 2 | PolyPeptide Group |
https://alibaba.com/supplier/bachem-peptides.html | 1 | Bachem |
https://bioscience.co.uk/userfiles/pdf/Bachem%20Catalog_and_Custom_Peptides.pdf | 1 | Bachem |
These pages are candidates for review, not confirmed errors. Citation appearances are counted across the captured answers and are not added again for each company.
The publisher list should be prioritized by how often each page appeared across captured answers and by how many of the peer companies it touches. The most-cited pages are the natural first reviews, but appearance counts do not show that a page shaped an answer.
Each review should confirm what the page currently says before any request is drafted. Pages covering several companies may need separate checks, and a request should only follow verified evidence of an inaccuracy.
What we'd prioritize first
Period | Deliverable | Completion criterion |
|---|---|---|
Days 1–30 | Baseline scorecard, scoped fact-review register and page/source shortlist | Each record has an owner, evidence requirement and review status |
Days 31–60 | Approved page briefs and justified publisher requests | Separate confirmed edits, no-change decisions, requests and responses |
Days 61–90 | Buyer-content briefs and a fresh scorecard | Record work completed separately from measured answer outcomes and comparability limits |
Start with the baseline scorecard and a scoped fact-review register, because the recorded conflicts are the most concrete finding and they gate any correction work. Pair that with a shortlist of owned pages and third-party sources drawn from the supplied candidates.
Once facts are confirmed, move to page briefs and justified publisher requests, keeping confirmed edits, no-change decisions and outstanding requests separate. Later, draft buyer-question content and refresh the scorecard, recording completed work apart from measured answer outcomes.
Methodology and conclusion
Questions This Section Answers
- What do the Peptide API Manufacturing sample and source-review limits allow us to conclude?
This edition includes all relevant captured answers, including buyer questions reserved from the limited email report. Every captured answer was screened and every relevant answer was included in the figures. Mentions require the company to be identified in the answer; incidental uses of its name as an ordinary word are not counted. Mentions require the company to be identified in the answer; incidental uses of its name as an ordinary word are not counted. Ahrefs queries return a bounded brand-query sample, not every AI answer available.
This report covers 2026-11. The exact dates when the original AI answers were collected have not been verified. The visibility rates use 303 answers that met the benchmark's inclusion rules. A company is recommended only when the answer both endorses it and uses positive wording. Top 3 and first-place counts are part of those recommendations, not extra recommendations.
An answer can mention or recommend several companies, so company counts cannot be added to find the number of distinct answers. The net sentiment score is positive minus negative mentions, divided by all company mentions; it describes answer wording, not customer satisfaction.
The wider citation analysis covers 359 captured answers and 2381 appearances of cited URLs. Citation appearances across all captured answers differ from the number of benchmark answers citing a page and the number that also recommend a company. The current contents of cited pages and disputed company claims still need independent verification.
Monthly sample coverage:
Reporting month | Answers included | AI services covered | Services |
|---|---|---|---|
Nov 2026 | 303 | 6 | ChatGPT, Copilot, Gemini, Google AI Mode, Google AI Overviews, Perplexity |
Earlier editions (July 2026, August 2026, September 2026 and October 2026) used a narrower set of questions. This edition includes all captured answers screened as relevant and establishes a broader baseline. Earlier figures remain in the archive; they are not used to claim a change in performance.
Future editions using the same screening scope can be compared against this baseline.
These figures describe how often companies appeared and were endorsed in the captured answers, not customer preference or market share. Mentions, recommendations and placements are nested, so company counts cannot be added to find distinct answers, and the sentiment measure reflects answer wording only.
The exact collection dates for the original answers are unverified, and cited pages still need independent checking. This edition sets a broader baseline; future editions using the same screening scope can be compared with it, without treating the comparison as proof that any work caused a change.
Related research
This analysis is based on the source benchmark: Peptide API Manufacturing AI visibility benchmark
/ Learn More
Understanding AI search visibility.
AI search experiences create answers by pulling information from many places online and summarizing it into a single response.
What Is AI Citation Intelligence?
What Is Citation Architecture?
What Is Generative Engine Optimization?
What Is AI Share of Voice?
Archived editions
Browse earlier published research snapshots for this article. The latest edition remains at the current URL.


